Hepatitis and IPT
IPT has been shown to be very fast and effective in treating
viral hepatitis, as well as other liver conditions.
Apparently IPT is very successful at delivering medications into the tissues
of the liver.
Dr. Perez Garcia y Bellon 2, I recall,
had success in treating hepatitis,
although I do not have any written anecdotes at hand.
His student, Dr. Paquette, in his book Medicine of Hope,
presents two cases of viral hepatitis
where remarkable improvement was achieved after just one IPT
And Dr. Perez Garcia 3 has told me about a case of supposedly incurable hepatitis C
that he was able to treat so successfully that the disease was no longer
detectable and the patient was restored to health. This disease and this
case deserve further discussion, as follows.
Hepatitis C briefing:
In the United States alone, 4 million people
have the Hepatitis C virus (HCV), four times the number infected by HIV. Each year
in the US, 33,000 new HCV infections occur, and about 10,000 people die. These numbers are
expected to increase dramatically. Worldwide, there are many more. The
infection is spread primarily through needle sharing among drug users, although there is
some risk from accidental needle sticks, blood products before 1992, chronic blood
dialysis, and frequent sexual contact. Liver problems from HCV can take decades to
develop. Current drug treatments using ribavirin and interferon cost $8,000 to
$20,000 per year, and are usually only partly effective. End stage HCV disease puts
patients who can afford $250,000 to $300,000 in the waiting line for liver transplants.
Patients who cannot afford treatments or who cannot wait long enough for a
transplant, are out of luck.
IPT for Hepatitis C: Dr. Perez Garcia 3
told me that he treated one woman who had hepatitis C. Presumably he used an antiviral drug and
other helpful drugs in the IPT mix. After several treatments, she was completely
restored to health, according to the standard tests. Unfortunately, the records of
her case were lost by a doctor in the US.
Successful treatment of HCV infection with
IPT would not be surprising in light of its anecdotal record in treatment of other viral
diseases, including herpes and HIV. IPT may succeed by getting therapeutic
quantities of the antiviral drug into compartments of the body that are normally less
accessible to medication, and perhaps by stimulating the immune system.
This case certainly deserves follow-up in a larger clinical setting,
ideally with Dr. Perez Garcia 3 as instructor and advisor to the medical team. Even
a rumor of such a treatment deserves follow-up, and we have, in the whole IPT
story, much more than that. If a few IPT treatments, costing a few hundred
dollars, can eliminate the need for $8K to $20K per year for
only-partly-effective chronic drug treatment, or $300K for a liver transplant,
and the patient can walk away free of the disease, then a lot of money can be
saved and a lot of patients will become very happy.
Let's do it.